Global segment ranking · Healthtech › Medtech
The world’s most valuable imaging & medical ai startups
Imaging devices and the AI that reads medical images and signals: radiology, pathology, dental, skin, eye, cardiac and endoscopy AI, AI screening, whole-body scan clinics and new imaging hardware. Ranked worldwide by AI-estimated valuation, with listed pure players shown in grey at their market value for reference. The market sets the value; AI models estimate it.
Key metrics for this segment: key milestone. Figures as published by each company or the press, dated, not recalculated. The AIs weigh them alongside funding history and comparables.
Not in this segment. Listed, so not ranked: HeartFlow, Butterfly Network and Lunit (shown in grey), and Vuno, Airdoc, Hyperfine and Nano-X Imaging. Bought: Paige (Tempus AI), Kheiron (RadNet), Caption Health; Annalise.ai belongs to Harrison.ai; DeepHealth is owned by RadNet. In other segments: clinical documentation and ambient scribes under Clinical software, connected monitoring devices under Connected devices. A company appears in one segment only. Method
The segment at a glance
25companies ranked
0companies on the radar
13countries in the ranking
3listed benchmarks
Sources: Company announcements, Bloomberg, Reuters, TechCrunch, STAT, Fierce Biotech, MedTech Dive, AuntMinnie, Radiology Business, Sifted, Calcalist, Inc42 and market data for listed companies. Intention counters will be shown above a threshold of amount and number of Backers.
Rankings by region
Filter the ranking and the Radar. Ranks stay worldwide. Regional pages: Asia · Europe · Middle East & North Africa · North America · Oceania.Global ranking · Imaging & medical AI
Snapshot28 Oct 2026A snapshot taken on 28 Oct 2026
This ranking shows the startups as they stood on 28 Oct 2026. Funding rounds, valuations and other events announced after that date are not included yet. They will be taken into account in the next edition, scheduled for 26 Apr 2027.
Spotted a more recent round? Tell us →First edition: no movements yet.
This ranking shows the startups as they stood on 28 Oct 2026. Funding rounds, valuations and other events announced after that date are not included yet. They will be taken into account in the next edition, scheduled for 26 Apr 2027.
Spotted a more recent round? Tell us →First edition: no movements yet.
World · 25 ranked companies
| # | Company | Last round · Key metrics | AI valuation | Pool of InterestsInterest: a free, non-binding declaration on a company, or on a sector within an area, made during the free phase of a pool. Pool: all the Interests declared on the same target. This column shows the number of Backers and the combined amount of their tickets, to validated members only. Terms for Backers → | BackBacking a startup on Uback (pronounced “you back”) can be done in two ways: Interest · free: a non-binding declaration that signals your demand for a company or a sector. You can move or withdraw it at any time, with up to 5 at once. Intention · coming soon: a paid, confirmed declaration, still non-binding. Once its pool reaches critical mass, it is presented to a company by a partner desk. Neither is an order nor a commitment to invest. Terms for Backers → |
|---|---|---|---|---|---|
| 1 | Neko Health#3 in SwedenOperates clinics offering a one-hour non-invasive full-body scan that combines imaging, sensors and blood tests with AI analysis to detect health risks early. | Series C · USD 700M · Jul 2026More than 100,000 people scanned · Jul 2026 | Last known equity round: Series C · USD 700M · Jul 2026 (Lightspeed, O.G. Venture Partners, Atomico, General Catalyst) Published valuation: USD 7bn (Jul 2026)Method |
Be the first | Back |
| — | HeartFlowListed · Nasdaq · HTFL | USD 5.08bnMarket cap · Oct 2026Listed company · not ranked | |||
| — | Butterfly NetworkListed · NYSE · BFLY | USD 1.71bnMarket cap · Oct 2026Listed company · not ranked | |||
| 2 | DentalMonitoring#21 in FranceProvides smartphone-based remote dental monitoring with AI analysis of patient-taken intraoral scans, letting orthodontists follow treatments without in-office visits. | Growth round · USD 100M · Feb 2026Key metrics not disclosed | Last known equity round: Growth round · USD 100M · Feb 2026Method | Be the first | Back |
| 3 | PathAIDevelops AI-powered pathology software and lab services that analyse tissue slide images to support cancer diagnosis and drug development for pharma and laboratories. | Series C · USD 165M · May 2021Key metrics not disclosed | Last known equity round: Series C · USD 165M · May 2021Method | Be the first | Back |
| 4 | Aidoc#41 in IsraelProvides hospitals with an AI platform and foundation model that analyse CT and other imaging studies to flag urgent findings such as strokes and embolisms for radiologists. | Series E · USD 150M · Apr 2026FDA clearance in Jan 2026 for an AI triage tool covering 14 indications · Jan 2026 | Last known equity round: Series E · USD 150M · Apr 2026 (Goldman Sachs Asset Management)Method | Be the first | Back |
| 5 | InfervisionDevelops AI software that reads CT, X-ray and other scans to detect lung nodules, fractures, stroke and other conditions for hospitals in China and abroad. | Series D · USD 139M · Jul 2021Key metrics not disclosed | Last known equity round: Series D · USD 139M · Jul 2021 (Goldman Sachs, Z-Park Fund, CCB Trust)Method | Not open to BackersCompanies based in mainland China are ranked like any other startup, but Uback does not open pools on them: capital controls and offshore (VIE) structures make minority deals impractical for our Backers. You can still declare an interest in this segment → |
|
| 6 | PrenuvoRuns a network of clinics offering whole-body MRI screening scans, read by radiologists with AI support, to detect cancers and other conditions early in consumers. | Series B · USD 120M · Feb 2025110,000+ members and 17 company-owned centres in North America · Feb 2025 | Last known equity round: Series B · USD 120M · Feb 2025 (Forerunner Ventures, Left Lane Capital; Felicis)Method | Be the first | Back |
| — | LunitListed · KOSDAQ · 328130 | USD 580MMarket cap · Aug 2026Listed company · not ranked | |||
| 7 | Harrison.ai#11 in AustraliaDevelops AI models that read radiology and pathology images, including chest X-ray and head CT, to help clinicians in hospitals and imaging networks detect findings. | Series C · USD 112M · Feb 2025Key metrics not disclosed | Last known equity round: Series C · USD 112M · Feb 2025Method | Be the first | Back |
| 8 | CleerlyProvides AI software that analyses coronary CT angiography scans to quantify plaque and stenosis, helping cardiologists assess and manage heart disease risk. | Series C (extension) · USD 106M · Dec 2024Key metrics not disclosed | Last known equity round: Series C (extension) · USD 106M · Dec 2024 (Insight Partners, Battery Ventures)Method | Be the first | Back |
| 9 | Rad AIBuilds generative AI tools that draft radiology report impressions and automate follow-up and workflow tasks for radiologists and health systems. | Series C · USD 60M · Jan 2025Used by nearly half of US health systems and imaging practices (company claim) · Jan 2025 | Last known equity round: Series C · USD 60M · Jan 2025 (Transformation Capital) Published valuation: USD 520M (Jan 2025)Method |
Be the first | Back |
| 10 | Viz.aiRuns an AI care-coordination platform that analyses CT and other scans to detect suspected strokes and other conditions and alerts care teams in hospitals. | Series D · USD 100M · Apr 2022Key metrics not disclosed | Last known equity round: Series D · USD 100M · Apr 2022Method | Be the first | Back |
| 11 | Qure.aiDevelops AI software that reads chest X-rays, CT scans and other images to detect tuberculosis, lung cancer, stroke and trauma for hospitals and public screening programmes. | Series D · USD 65M · Sep 2024Used at 3,000+ care sites in 90+ countries · Sep 2024 | Last known equity round: Series D · USD 65M · Sep 2024 (Lightspeed, 360 ONE Asset; Merck Global Health Innovation Fund, Kae Capital)Method | Be the first | Back |
| 12 | AI Medical Service#19 in JapanDevelops AI software that analyses endoscopy video in real time to help gastroenterologists detect gastric and other gastrointestinal cancers. | Series C · USD 62.5M · Apr 2022Key metrics not disclosed | Last known equity round: Series C · USD 62.5M · Apr 2022Method | Be the first | Back |
| 13 | UltromicsDevelops FDA-cleared AI that analyses routine echocardiography ultrasound images to detect heart failure and other cardiac conditions for hospitals. | Series C · USD 55M · Jul 2025EchoGo platform FDA cleared and Medicare reimbursed · Jul 2025 | Last known equity round: Series C · USD 55M · Jul 2025 (L&G, Lightrock, Allegis Capital, GV)Method | Be the first | Back |
| 14 | OverjetProvides dental practices and insurers with FDA-cleared AI that analyses dental X-rays to detect and measure decay and bone loss and support claims review. | Series C · USD 53.2M · Mar 2024Payer partners cover 120M+ members · Mar 2024 | Last known equity round: Series C · USD 53.2M · Mar 2024 (March Capital; General Catalyst, Insight Partners, E14 Fund, Crosslink Capital)Method | Be the first | Back |
| 15 | Quibim#25 in SpainDevelops AI imaging biomarker software that extracts quantitative data from MRI and CT scans for radiologists and pharmaceutical clinical trials. | Series A · USD 50M · Jan 2025Key metrics not disclosed | Last known equity round: Series A · USD 50M · Jan 2025Method | Be the first | Back |
| 16 | ProsciaOffers a digital pathology platform that lets laboratories and pharmaceutical companies manage whole-slide images and deploy AI algorithms for diagnosis and research. | Growth round (type not stated) · USD 50M · Mar 2025Used by 16 of the top 20 pharma companies · Mar 2025 | Last known equity round: Growth round (type not stated) · USD 50M · Mar 2025 (Insight Partners; AI Capital Partners, Triangle Peak Partners)Method | Be the first | Back |
| 17 | Ibex Medical AnalyticsDevelops AI pathology software that analyses digitised biopsy slides to detect and grade prostate, breast and other cancers for laboratories and pathologists. | Series B · USD 38M · Mar 2021Key metrics not disclosed | Last known equity round: Series B · USD 38M · Mar 2021 (Octopus Ventures, 83North; aMoon, Planven Entrepreneur Ventures, Dell Technologies Capital)Method | Be the first | Back |
| 18 | PocketHealthOffers a patient-facing platform that lets people access, store and share their medical images and reports, used by hospitals and imaging centres to replace CDs. | Series B · USD 33M · Mar 2024Used by 775+ hospitals and outpatient imaging centres · Mar 2024 | Last known equity round: Series B · USD 33M · Mar 2024 (Round13 Capital; Samsung, Deloitte investment arms, Questa Capital, Radical Ventures)Method | Be the first | Back |
| 19 | GleamerDevelops AI software that reads X-rays, mammograms and other images to detect fractures and lesions, assisting radiologists and emergency physicians in hospitals and clinics. | Series B · USD 29.5M · Jun 2023Key metrics not disclosed | Last known equity round: Series B · USD 29.5M · Jun 2023 (Supernova Invest, Heal Capital)Method | Be the first | Back |
| 20 | Omniscient Neurotechnology#36 in AustraliaBuilds brain-mapping software that turns standard MRI scans into personalised connectomic maps to help neurosurgeons and neurologists plan treatments. | Series D · USD 27.2M · May 2026Key metrics not disclosed | Last known equity round: Series D · USD 27.2M · May 2026Method | Be the first | Back |
| 21 | Skin AnalyticsDevelops AI medical device software that assesses dermoscopic images of skin lesions to detect skin cancer, deployed in NHS dermatology pathways. | Series B · USD 19.8M · Apr 2025Deployed at 26 NHS sites; 150,000+ patients in its pathways · Apr 2025 | Last known equity round: Series B · USD 19.8M · Apr 2025 (Intrepid Growth Partners)Method | Be the first | Back |
| 22 | Promedius#35 in South KoreaDevelops AI software that reads chest X-rays to estimate bone density and flag osteoporosis risk for radiologists and clinicians. | Series B · USD 15.4M · Jun 2026Key metrics not disclosed | Last known equity round: Series B · USD 15.4M · Jun 2026Method | Be the first | Back |
| 23 | CARPL.aiRuns a vendor-neutral platform where hospitals and radiology groups test, deploy and monitor third-party imaging AI algorithms within their clinical workflows. | Series A · USD 10M · Jul 2026Key metrics not disclosed | Last known equity round: Series A · USD 10M · Jul 2026 (IFC)Method | Be the first | Back |
| 24 | VaraProvides breast cancer screening software that uses AI to triage and pre-read mammograms for radiologists in national screening programmes in Germany and emerging markets. | Series A (per Seedtable; article says 'financing round') · USD 8.9M · Oct 2024Used in about 40% of German screening centres; 80,000+ women a month · Oct 2024 | Last known equity round: Series A (per Seedtable; article says 'financing round') · USD 8.9M · Oct 2024 (IBB Ventures impact fund, Smart Family Office, FJH)Method | Be the first | Back |
| 25 | Swift MedicalProvides a smartphone-based platform that uses AI to measure and document wounds from photos, helping nurses and care facilities track healing and standardise wound care. | Financing (type not stated) · USD 8M · Jan 2024Used by 4,000+ healthcare facilities and 20,000+ clinicians · Jan 2024 | Last known equity round: Financing (type not stated) · USD 8M · Jan 2024 (BDC Capital Women in Technology Venture Fund, Virgo Investment Group funds)Method | Be the first | Back |
Back · Backing on Uback (pronounced “you back”) means declaring an Interest (free) or an Intention (coming soon). Backing does not mean that this company is raising funds or that a shareholder is selling shares, and it is not a commitment to invest. Any deal, through a funding round or a sale by an existing shareholder, is handled by a partner desk: the Fundraising Desk of the country for a round, the Secondary Sales Desk assigned to the company for a sale. · Terms
Corporate investor? Back the startups of your own segment
No ranked company in this region yet: see the Radar.
Ranking in descending order of AI-estimated valuation, based on public information, with no human intervention on the order. The valuations, ranges and brackets shown are editorial estimates produced by AI, purely indicative and imperfect by nature: neither a financial valuation, nor an offer, nor investment advice. Only the market sets a company’s value, through a funding round or a sale. Ranking established by Claude (Anthropic) from public information, following the published rules. A consensus of several AIs will apply from 1 December 2026. Eligibility: at least $1M raised in equity, non-listed company, main activity in this segment (imaging & medical ai). Country shown is the country of main operations. Request a correction · Full method →
Get every new ranking
New entries, exits and movements, at every edition.
No data passed on to third parties. See our Privacy policy.
Challengers
A registered company raising funds that is not in the ranking will be able, for a fee, to appear in a separate list labelled “Challengers”, for a set period, with a memo available to verified Backers. The listing has no effect on the ranking. Not open yet.
Sponsored space · no Challenger listed yet
Radar · known eligible companies, not ranked
Sorted by date of last round, with no judgement and no AI call.
No company on the radar in this region yet.
Listed benchmarks
Not ranked: no intention is possible on a listed company.
- HeartFlow · United StatesNasdaq · HTFL · USD 5.08bn (Oct 2026)
- Butterfly Network · United StatesNYSE · BFLY · USD 1.71bn (Oct 2026)
- Lunit · South KoreaKOSDAQ · 328130 · USD 580M (Aug 2026)
Sources and method for this segment
Calendar. Global segment rankings are published twice a year. Next edition: April 26, 2027.
Eligibility. At least $1M raised in equity, non-listed company, main activity in this segment (imaging & medical ai). A company appears in one segment only.
Sources. Company announcements, Bloomberg, Reuters, TechCrunch, STAT, Fierce Biotech, MedTech Dive, AuntMinnie, Radiology Business, Sifted, Calcalist, Inc42 and market data for listed companies.